Yu Zhong, Zhong Wa, Tan Zhi-Ming, Wang Ling-Yun, Yuan Yu-Hong
Departments of *Gastroenterology and Hepatology †Network Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Am J Clin Oncol. 2015 Jun;38(3):322-5. doi: 10.1097/COC.0b013e3182a46782.
Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer. Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. The pooled data (n=2017 patients) indicated that the overall survival data were homogenous among the studies (Q=4.371; I=31.37%; P=0. 224). The combined HR significantly favors GEM over the other treatments. The overall HR was 0.88 (range, 0. 720 to 0.940; P=0.014). The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer.
吉西他滨（GEM）是一种已被批准用于治疗不可切除胰腺癌的药物；然而，其在治疗可切除胰腺癌中的作用尚不清楚。本研究的目的是调查辅助性吉西他滨治疗对可切除胰腺癌患者生存作用的证据。我们检索了四项关于辅助性吉西他滨治疗可切除胰腺癌患者的III期随机试验，并在本荟萃分析中使用总生存风险比（HR）；两项研究将吉西他滨治疗与最佳支持治疗进行了比较，另外两项研究则与5-氟尿嘧啶/亚叶酸治疗进行了比较。汇总数据（n = 2017例患者）表明，各研究间的总生存数据具有同质性（Q = 4.371；I² = 31.37%；P = 0.224）。合并后的HR显著支持吉西他滨优于其他治疗。总体HR为0.88（范围，0.720至0.940；P = 0.014）。结果表明，与胰腺癌切除术后的其他治疗相比，吉西他滨可延长总生存期。
